Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Supergen (supg) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (48)	1/19/1999 1:06:00 PM
From: JEM	Read Replies (1) \| Respond to of 124

So it seems, from what I've read so far. FWIW, for those interested, from what I recall from my own research and conversations with Jerry at SPTA last year, the Spartaject busulfan technology was developed by the same person responsible for developing the oral busulfan regime for leukemia in the 70's that ended up saving saved so many people's lives who had leukemia back then - Dr. Louise Grochow. There have been some pretty reputable and renowned folks/institutions involved with this project. The SPTA thread here on SI has been dead for some time, but if you're interested, I've been posting most of SPTA's news since last spring. Best of luck to all of us! JEM